• "Given that there hasn't been a new drug approved for SLE since before man walked on the moon, we suspect market projections will be all over the map for this drug."

-Cory Kasimov, analyst with J.P. Morgan, in a research note 07/21/09 about Human Genome Sciences Inc.'s surprise Phase III win with lupus drug Benlysta

• "Those are the kind of programs that drove the dyslipidemia and hypertension markets into the $40 billion range from starting . . . in the multi-billion-dollar range."

-Michael Narachi, president and CEO of Orexigen Therapeutics Inc., commenting 07/20/09 on the potential of large outcomes studies to boost sales of obesity drugs like Contrave

• "Gilead: GSK called - It wants its HIV franchise back."

-Joshua Schimmer, analyst with Leerink Swann, in a research note 07/20/09 warning Gilead Sciences Inc. to watch out for competition from GlaxoSmithKline plc's integrase inhibitor, GSK1349572